EcoR1 Capital, LLC recently announced the acquisition of new stake in Immunome Inc (NASDAQ:IMNM). This fresh investment now brings its stake to 9.08% valued currently at $41.51 million. In addition, Redmile Group LLC raised its holdings by 3.88 million to 3.88 million shares. And Point72 Asset Management LP has lifted its position by 30.56% or 0.13 million shares – to 0.55 million shares.
With over 0.48 million Immunome Inc (IMNM) shares trading Friday and a closing price of $13.16 on the day, the dollar volume was approximately $6.28 million. The shares have shown a positive half year performance of 69.37% and its price on 01/12/24 gained nearly 10.13%. Currently, there are 42.73M common shares owned by the public and among those 32.22M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 8 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 8 of these insider trades were purchases, accounting for 581,400 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Immunome Inc are Vanguard Total Stock Market ETF, Vanguard Extended Market Index Fu, and IAM Prentice Long Short Equity UC. Vanguard Total Stock Market ETF owns 0.25 million shares of the company’s stock, all valued at over $2.73 million. IAM Prentice Long Short Equity UC bought 0.12 million shares to bring its total holdings to over 0.12 million shares at a value of $1.32 million. IAM Prentice Long Short Equity UC now owns shares totaling to 0.29% of the shares outstanding.
However, the script later moved the day high at 13.24, up 10.13%. The company’s stock has a 5-day price change of 18.35% and 57.04% over the past three months. IMNM shares are trading 22.99% year to date (YTD), with the 12-month market performance up to 230.65% higher. It has a 12-month low price of $3.83 and touched a high of $12.67 over the same period. IMNM has an average intraday trading volume of 178.41K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 31.92%, 49.09%, and 82.91% respectively.
Institutional ownership of Immunome Inc (NASDAQ: IMNM) shares accounts for 23.68% of the company’s 42.73M shares outstanding. Mutual fund holders own 12.09%, while other institutional holders and individual stakeholders account for 21.95% and 1.73% respectively.
It has a market capitalization of $562.33M and a beta (3y monthly) value of 1.53. The earnings-per-share (ttm) stands at -$1.86. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.24% over the week and 8.56% over the month.
Analysts forecast that Immunome Inc (IMNM) will achieve an EPS of $0 for the current quarter, -$0.23 for the next quarter and -$1.08 for 2024. The lowest estimate earnings-per-share for the quarter is $0 while analysts give the company a high EPS estimate of $0. Comparatively, EPS for the current quarter was -$0.75 a year ago. Earnings per share for the fiscal year are expected to increase by 66.18%, and 2.87% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 2 brokerage firm advisors rate Immunome Inc (IMNM) as a “Strong Buy” at a consensus score of 1.00. Specifically, 2 Wall Street analysts polled rate the stock as a buy, while 0 of the 2 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the IMNM, a number of firms have released research notes about the stock. Wedbush stated their Outperform rating for the stock in a research note on December 19, 2023, with the firm’s price target at $12.
